Champions Oncology, Inc. · NASDAQ:CSBR
Champions Oncology — Investor Presentation (March 2021)
23 slides from Champions Oncology's investor presentation, March 2021
Slide 1: Accelerating Drug Discovery: Investor Relations Presentation
Creating Greater Certainty in the Fight Against Cancer ACCELERATING DRUG DISCOVERY Investor Relations Presentation March 2021
Slide 2: Notice of Forward-Looking Statements
Notice of Forward-Looking Statements This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking
Slide 3: Our Mission
OUR MISSION… Transforming Cancer R&D Through Innovative Pharmacology, Biomarker & Data Platforms 2021 Champions Oncology, All Rights Reserved 3 NASDAQ: CSBR 3
Slide 4: Introducing Champions Oncology
Introducing Champions Oncology A Global Organization Built Through Offering Innovative Research Platforms 30+% Investors: FY 2016-2019 Revenue Growth/Year AAALAC Accredited Battery 130 Ventures employees in 6 Countries 400+ •I New Enterprise CLIA Certified Biopharma customers globally Associates 500
Slide 5: Business Milestones
Business Milestones Ronnie Morris & Joel Ackerman Profitability join Champions Databank reaches reached Launched GCP Flow 1,000 models Cytometry Services 2011 2012 2015 2016 2018 2019 Strategic decision to IO platforms Ex vivo platforms aggressively grow launched launched biologic and computational
Slide 6: Senior Leadership Team
Senior Leadership Team Champions Oncology’s Management positions the future of the company for aggressive growth Ronnie Morris, MD Michael Ritchie, PhD, MBA Phil Breitfeld, MD David Miller, MBA President & Chief Executive Chief Commercial Officer Chief Innovation & Chief Financial Officer Officer St
Slide 7: The Current Dilemma In Oncology Drug Development
The Current Dilemma In Oncology Drug Development Drug Discovery Preclinical Clinical Trials Regulatory Approval • Dwindling discovery pipelines • The cumulative duration of discovery from concept to commercialization is unacceptably Post-market surveillance 5,000-10,000 250 5 1 New lengthy compounds
Slide 8: Champions' Technology-Enabled Research Platforms
Creating Greater Certainty in the Fight Against Cancer CHAMPIONS’ TECHNOLOGY- ENABLED RESEARCH PLATFORMS
Slide 9: Champions Foundational Platform: Simulating Patient Responses with PDX Modeling
Champions Foundational Platform A Company Built on Innovation - Simulating Patient Responses with PDX Modeling Patient Implant Treatment Measurement Patient tumor is Mice are dosed Effect of each therapy Implanted in immune With different anti-tumor on tumor growth is measured Compromised mice thera
Slide 10: The World's Preeminent Living Biobank
The World’s Preeminent Living Biobank Colorectal 15 10 Champions’ PDX Data Bank: 17 Sarcoma 17 48 • 87-94% clinical response correlation Lung (NSCLC/SCLC) 19 170 • ~1500 tumor models Pancreatic 25 Head and neck • 45+ tumor types 26 33 Breast • Fully annotated • Molecular characterization Ovarian • C
Slide 11: Champions' Oncology Ecosystem
Champions’ Oncology Ecosystem Accelerating drug discovery through innovative pharmacology, biomarker and data platforms • In vivo Pharmacology In Vivo PDX & o Simulating clinical trials Cell Lines o Drug efficacy studies o Pharmacodynamic analysis • Ex Vivo Pharmacology Ex Vivo/In Vitro o Extensive
Slide 12: Champions' Oncology Ecosystem
Champions’ Oncology Ecosystem Accelerating drug discovery through innovative pharmacology, biomarker and data platforms • Advanced flow cytometry platforms o 24 color o Superior analytic methodology Flow Cytometry o Complex study design • Comprehensive array of histology o IHC and IF Histology & IHC
Slide 13: The Lumin Platform
The Lumin Platform Informatics SaaS Informatics Consulting Genomic Validation A Comprehensive Biomarker Platform NASDAQ: CSBR 2021 Champions Oncology, All Rights Reserved 13
Slide 14: Champions' Oncology Ecosystem
Champions’ Oncology Ecosystem Accelerating drug discovery through innovative pharmacology, biomarker and data platforms In Vivo PDX & Flow Cytometry Cell Lines Ex Vivo/In Vitro Histology & IHC PDX & Cell Lines Functional Humanized Models Plate-Based Assays mPDX, Syngeneic Sequencing & huSyngeneic NA
Slide 15: Oncology Market Overview
ONCOLOGY MARKET OVERVIEW 15
Slide 16: Oncology Market Continues To Soar
Oncology Market Continues To Soar Oncology market will double between 2019 and 2024 • The oncology CRO market is expected to reach $44B by 2021 • Clinical flow market is expected to reach $1B by 2021 Global Market Sizes by 2021 Global Pharma $752B 6% CAGR Global Oncology $175B 12% CAGR Global Oncolo
Slide 17: Market Positioning And Brand Image
Market Positioning And Brand Image Industry Leader Biggest, brightest & best Innovative Offerings Pioneering & comprehensive Trusted & Quality Flexible & consultative operational delivery Scientific Superiority Strong scientific expertise in oncology at all levels NASDAQ: CSBR 2021 Champions Oncolog
Slide 18: Financial Overview
C. HAMPIONS ONCOLOGY 18
Slide 19: Revenue Growth
Revenue Growth NASDAQ: CSBR Annual Revenue Trend 45,000 39,500 • 30% revenue CAGR from FY 2016 – FY 2020 40,000 35,000 32,122 • FY 2021 projected revenue 30,000 27,070 based on 20%-25% revenue 25,000 growth guidance 20,215 20,000 • Guidance revised upwards on December 14 earnings call 15,410 15,000
Slide 20: Financial Results
Financial Results 3 Months Ended January 31, 2021 2020 (Numbers in 000’s) Q3 2021 Q3 2020 2021 HigQ1 2021 Highlights Oncology Services Revenue $10,812 $9,012 Q3 2021hlights Highlights Costs and Operating Expenses • 20% year over year Cost of Oncology Servcies $4,777 $4,305 revenue growth Research an
Slide 21: Financial Results
Financial Results 9 Months Ended January 31, 2021 2020 (Numbers in 000’s) Q3 2021 Q3 2020 Oncology Services Revenue $30,476 $23,374 Q3 2021 Highlights Costs and Operating Expenses Cost of Oncology Servcies $15,662 $11,955 Research and Development 5,110 4,026 • 30% year over year revenue Sales and Ma
Slide 22: Strategies For Continued Growth
Strategies For Continued Growth Continued Geographic Expansion of Expansion Services Leveraging people, process technology, and Leveraging Data deep penetration into BioPharma Champions Growth Engine NASDAQ: CSBR 2021 Champions Oncology, All Rights Reserved 22
Slide 23: Corporate Contacts
Corporate Contacts: Ronnie Morris, MD – President & CEO (201) 808-8401 RMorris@ChampionsOncology.com David Miller, MBA – CFO (551) 206-8104 DMiller@ChampionsOncology.com
Champions Oncology — Investor Presentation (March 2021) on 6ix